Evidence map›Paper›PMID 36611432›Full record

ArticleDiagnostics (Basel, Switzerland)2023

Cervicovaginal-Microbiome Analysis by 16S Sequencing and Real-Time PCR in Patients from Novosibirsk (Russia) with Cervical Lesions and Several Years after Cancer Treatment.

Mikhail K Ivanov, Evgeny V Brenner, Anastasia A Hodkevich, Victoria V Dzyubenko, Sergey E Krasilnikov, Alphiya S Mansurova, Irina E Vakhturova, Eduard F Agletdinov, Anastasia O Shumeikina, Alyona L Chernyshova and 1 more

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. The Interplay Between Cervicovaginal Microbiota Diversity,Healthcare (Basel, Switzerland) · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Mikhail K IvanovDepartment of the Structure and Function of Chromosomes, Institute of Molecular and Cellular Biology, Novosibirsk 630090, Russia.ORCID 0000-0001-7503-2435
Evgeny V BrennerAO Vector-Best, Novosibirsk 630117, Russia.
Anastasia A HodkevichAO Vector-Best, Novosibirsk 630117, Russia.
Victoria V DzyubenkoAO Vector-Best, Novosibirsk 630117, Russia.
Sergey E KrasilnikovInstitute of Oncology and Neurosurgery, E. Meshalkin National Medical Research Center, Novosibirsk 630055, Russia.
Alphiya S MansurovaInstitute of Oncology and Neurosurgery, E. Meshalkin National Medical Research Center, Novosibirsk 630055, Russia.
Irina E VakhturovaHospital (Medsanchast) No. 168, Novosibirsk 630117, Russia.
Eduard F AgletdinovAO Vector-Best, Novosibirsk 630117, Russia.
Anastasia O ShumeikinaDepartment of Natural Sciences, Novosibirsk State University, Novosibirsk 630090, Russia.
Alyona L ChernyshovaCancer Research Institute, Tomsk National Research Medical Center of the Academy of Sciences, Tomsk 634009, Russia.
Sergei E TitovDepartment of the Structure and Function of Chromosomes, Institute of Molecular and Cellular Biology, Novosibirsk 630090, Russia.ORCID 0000-0001-9401-5737
State Research Center of Virology and Biotechnology VECTOR · RUMeshalkin National Medical Research Center · RUNovosibirsk State University · RUTomsk National Research Medical Center · RU

Funding

Fundamental Scientific Research Program FWGZ-2021-0014Russian Science Foundation 20-14-00074
6 · The paper itself

Abstract

Disturbed cervicovaginal-microbiome (CVM) structure promotes human papillomavirus (HPV) persistence and reflects risks of cervical lesions and cancer onset and recurrence. Therefore, microbiomic biomarkers may be useful for cervical disease screening and patient management. Here, by 16S rRNA gene sequencing and commercial PCR-based diagnostic kits, we profiled CVM in cytological preparations from 140 HPV-tested women (from Novosibirsk, Russia) with normal cytological findings, cervical lesions, or cancer and from 101 women who had recently received different cancer therapies. An increase in lesion severity was accompanied by higher HPV prevalence and elevated CVM biodiversity. Post-treatment CVM was found to be enriched with well-known microbial biomarkers of dysbiosis, just as in cervical disease. Nonetheless, concentrations of some skin-borne and environmental species (which gradually increased with increasing lesion severity)-especially

Indexed as

16S rRNA gene sequencingcancer treatmentcervical cancercervicovaginal microbiomeCutibacterium acneshigh-grade squamous intraepithelial lesionhuman papillomavirusLactobacillus inerspost-treatment effectreal-time PCR

Identifiers

PMID36611432
PMCPMC9818139
OpenAlexW4313389008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.